Anaplastic Thyroid Cancer Overview

Anaplastic thyroid carcinoma, also known as undifferentiated thyroid carcinoma, is a rare, highly aggressive malignant tumor accounting for 2 to 3 percent of all thyroid gland neoplasms. Anaplastic thyroid carcinoma continues to be one of the most deadly diseases worldwide and carries a very poor prognosis.

“Anaplastic Thyroid Cancer Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Anaplastic Thyroid Cancer Market.

The Anaplastic Thyroid Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Anaplastic Thyroid Cancer Pipeline Report:

• Companies across the globe are diligently working toward developing novel Anaplastic Thyroid Cancer treatment therapies with a considerable amount of success over the years. Anaplastic Thyroid Cancer Key players such as – AffyImmune Therapeutics, Faron Pharmaceuticals Ltd., Codiak BioScience, Shanghai Henlius Biotech, Taizhou Hanzhong biomedical co. LTD, Merck & Co, Takeda Oncology, and others, are developing therapies for the Anaplastic Thyroid Cancer treatment 
• Anaplastic Thyroid Cancer Emerging therapies such as – AIC100, FP-1305, CDK-002, HLX208, HX008, Pembrolizumab, Sapanisertib, and others are expected to have a significant impact on the Anaplastic Thyroid Cancer market in the coming years.
• In February 2022, Stanford University in collaboration with Merck Sharp & Dohme LLC initiated a Phase II trial of Pembrolizumab in metastatic or locally advanced anaplastic/undifferentiated thyroid cancer

Route of Administration

Anaplastic Thyroid Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

Molecule Type

Products have been categorized under various Molecule types, such as

• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

Anaplastic Thyroid Cancer Pipeline Therapeutics Assessment

• Anaplastic Thyroid Cancer Assessment by Product Type
• Anaplastic Thyroid Cancer By Stage and Product Type
• Anaplastic Thyroid Cancer Assessment by Route of Administration
• Anaplastic Thyroid Cancer By Stage and Route of Administration
• Anaplastic Thyroid Cancer Assessment by Molecule Type
• Anaplastic Thyroid Cancer by Stage and Molecule Type

DelveInsight’s Anaplastic Thyroid Cancer Report covers around 8+ products under different phases of clinical development like-

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Some of the key companies in the Anaplastic Thyroid Cancer Therapeutics Market include:

Key companies developing therapies for Anaplastic Thyroid Cancer are – Shanghai Henlius Biotech, AffyImmune Therapeutics, Inc., Taizhou Hanzhong biomedical co. LTD,  Bristol-Myers Squibb, Takeda Oncology, Merck Sharp & Dohme Corp., Genentech, Inc., VBL Therapeutics, Eli Lilly and Company,  Chia Tai Tianqing Pharmaceutical Group Co., Ltd., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Purple Biotech, Boston Pharmaceuticals, Xynomic Pharmaceuticals, Inc., Turning Point Therapeutics, Inc., Iovance Biotherapeutics, Inc., Hoffmann-La Roche, Hutchison Medipharma Limited, Theratechnologies, TransThera Sciences (Nanjing), Inc., Novartis Oncology, SOTIO Biotech AG, Ono Pharmaceutical, Debiopharm, Tmunity Therapeutics, Codiak BioSciences, Oncoceutics, GlobeImmune, C4 Therapeutics, Innovative Cellular Therapeutics, Applied Pharmaceutical, and others.

Emerging Anaplastic Thyroid Cancer Drugs Under Different Phases of Clinical Development Include:

• AIC100: AffyImmune Therapeutics
• FP-1305: Faron Pharmaceuticals Ltd.
• CDK-002: Codiak BioScience
• HLX208: Shanghai Henlius Biotech
• HX008: Taizhou Hanzhong biomedical co. LTD
• Pembrolizumab: Merck & Co
• Sapanisertib: Takeda Oncology

Get a Free Sample PDF Report to know more about Anaplastic Thyroid Cancer Pipeline Therapeutic Assessment-

https://www.delveinsight.com/sample-request/anaplastic-thyroid-cancer-pipeline-insight

Anaplastic Thyroid Cancer Pipeline Analysis:

The Anaplastic Thyroid Cancer pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Anaplastic Thyroid Cancer with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Anaplastic Thyroid Cancer Treatment.
• Anaplastic Thyroid Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Anaplastic Thyroid Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Anaplastic Thyroid Cancer market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Anaplastic Thyroid Cancer product details are provided in the report. Download the Anaplastic Thyroid Cancer pipeline report to learn more about the emerging Anaplastic Thyroid Cancer therapies

Anaplastic Thyroid Cancer Pipeline Market Drivers

• Rising prevalence of thyroid cancer
• Improving Healthcare Infrastructure
• Demand for New and Effective Drugs
• Increasing awareness about anaplastic thyroid cancer

Anaplastic Thyroid Cancer Pipeline Market Barriers

• High cost of treatment
• Adverse effects associated with the chemotherapy

Scope of Anaplastic Thyroid Cancer Pipeline Drug Insight    

• Coverage: Global
• Key Anaplastic Thyroid Cancer Companies: AffyImmune Therapeutics, Faron Pharmaceuticals Ltd., Codiak BioScience, Shanghai Henlius Biotech, Taizhou Hanzhong biomedical co. LTD, Merck & Co, Takeda Oncology, and others
• Key Anaplastic Thyroid Cancer Therapies: AIC100, FP-1305, CDK-002, HLX208, HX008, Pembrolizumab, Sapanisertib, and others
• Anaplastic Thyroid Cancer Therapeutic Assessment: Anaplastic Thyroid Cancer current marketed and Anaplastic Thyroid Cancer emerging therapies
• Anaplastic Thyroid Cancer Market Dynamics: Anaplastic Thyroid Cancer market drivers and Anaplastic Thyroid Cancer market barriers 

Request for Sample PDF Report for Anaplastic Thyroid Cancer Pipeline Assessment and clinical trials

Table of Contents

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report to know more about Anaplastic Thyroid Cancer drugs and therapies

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/r-and-d-analysis